U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended November 30, 2013

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from

 

Commission File No. 333-154989

 

ENTEST BIOMEDICAL, INC.

(Exact name of small business issuer as specified in its charter)

 

Nevada	26-3431263
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

 

4700 Spring Street, St 304, La Mesa, California 91942

(Address of Principal Executive Offices)

 

619 702 1404

(Issuer’s telephone number)

 

None

(Former name, address and fiscal year, if changed since last report)

 

 

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☑   No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐ No ☑

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

☐  Large accelerated filer	☐  Accelerated filer
☐  Non-accelerated filer	☑  Smaller reporting company

 

APPLICABLE ONLY TO CORPORATE ISSUERS:

 

As of January 14, 2014 there were 1,153,070,662 shares of common stock were issued and outstanding.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☐ No ☑

 

Transitional Small Business Disclosure Format (Check One) Yes ☐   No ☑

 

 

PART I - FINANCIAL INFORMATION

Item 1. - Financial Statements

 

ENTEST BIOMEDICAL, INC.
( A Development Stage Company)
Consolidated Balance Sheet
		As of	As of
		November 30, 2013	August 31, 2013
		(unaudited)
ASSETS
Current Assets
	Cash	2874	9,610
	Due from Affiliate	28663	34,895
	Current Portion of Prepaid Expenses	8000	8,000
Total Current Assets		39537	52,505
Property & Equipment (Net of Accumulated Depreciation)		1,919	1,919
Intangible Assets (Net of Accumulated Amortization)		78	270
TOTAL ASSETS		41534	54,694
LIABILITES AND STOCKHOLDERS' EQUITY
Current Liabilities
	Accounts Payable	100581	101,615
	Notes Payable	245554	272,644
	Convertible notes payable, net of discount	0	101,000
	Due to Other	8000	8,000
	Accrued Expenses	291754	258,313
Total Current Liabilities		645889	741,572
TOTAL LIABILITIES		645889	741,572
STOCKHOLDERS' EQUITY
Common Stock,  $0.001 par value, authorized 2,000,000,000 shares;
	issued and outstanding   561,856,768 shares and 1153070752
	as of August 31, 2013 and November 30, 2013 respectively	1,153,069	561,855
Preferred Stock , $0.001 par value 5,000,000 shares authorized,
	0 shares issued and outstanding as of November 30,2013  and August 31, 2013
	Series AA Preferred Stock, $0.001 par value 100,000 shares authorized,
	5,000 shares issued and outstanding at August 31, 2013  and
	as of November  30, 2013	5	5
	Series B Preferred	3201	3,201
	$0.001 par value, 4,400,000 shares authorized, 3,201,397
	issued and outstanding as of  August 31, 2013 and November 30, 2013
	NonVoting Convertible Preferred	0	24,775
	$1 par value, 200,000 shares authorized, 24,775 and 0
	issued and outstanding as of August 31, 2013 and November 30, 2013
Additional Paid in Capital		3,472,363	3,441,563
Contributed Capital		274,162	274,162
Accumulated Deficit		(5,507,155)	(4,992,439)
Total Stockholders' Equity		(604,355)	(686,878)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY		41,534	54,694
The accompanying Notes are an integral part
of these Financial Statements

 

 

 

 

 

 

 

 

 

 

 

ENTEST BIOMEDICAL INC.
( A Development Stage Company)
Consolidated Statement of Operations
		For the Three Months  ended	For the Three Months ended	From inception (August 22, 2008) to
		November 30, 2013	November 30, 2012	November 30, 2013
		(unaudited)	(unaudited)	(unaudited)
TOTAL REVENUE		0	0	0
COSTS AND EXPENSES
	Research and Development	0	0	145,794
	Rent Costs	9,348	8,988	218,308
	General and Administrative	66,600	103,493	2,034,077
	Incorporation Costs			408
	Consultant's Expenses	11,865	54,484	861,931
	Miscellaneous Expenses			78
	Total Costs and Expenses	87,813	166,965	3,260,596
OPERATING LOSS		(87,813)	(166,965)	(3,260,596)
OTHER INCOME AND EXPENSE
	Other Income	5,700	0	171,223
	Penalties on Convertible Debentures	0	0	(63,000)
	Loss on derecognition of assets due to divestiture	0	(22,906)	(22,906)
	Loss on Early Extinguishment of Debt	0	0	(18,647)
	Income generated from revenue	0	0	187,699
	Share Agreement
	Expenses incurred from Revenue
	Share Agreement	0	0	(145,362)
	Loss on Impairment of intangible	0	0	(683,333)
	assets
	Interest Expense	(8,481)	(9,667)	(111,122)
	Interest Expense attributable to
	amortization of discount	0	(61,904)	(537,215)
	Loss on Impairment of Goodwill	0	(405,000)	(405,000)
	Gain on derecognition of Liabilities due to
	Divestiture	0	61,168	61,168
	Expense attributable to issuance of common shares
	below par value	(420,369)	(49,294)	(476,712)
	Expense attributable to issuance
	of shares pursuant to contractual
	obligation	0	(26,868)	(56,779)
	Expense attributable to issuance of
	Non Voting Convertible Preferred
	Shares in connection with Stock
	Purchase Agreement	0	0	(75,000)
TOTAL OTHER INCOME AND EXPENSE		(423,150)	(514,471)	(2,174,986)
LOSS BEFORE INCOME TAXES		(510,963)	(681,436)	(5,435,582)
	income Taxes
NET LOSS		(510,963)	(681,436)	(5,435,582)
	Beneficial conversion feature
	attributable to issuance of NonVoting
	Preferred Stock	0	0	(32,142)
	NET LOSS  from continuing
	Operations	(510,963)	(681,436)	(5,467,724)
	Net Income (Loss) from discontinued operations	(3,753)	(31,210)	(39,431)
	NET LOSS available to common shareholders	(514,716)	(712,646)	(5,507,155)
	BASIC AND DILUTED EARNINGS
	(LOSS) PER SHARE FROM CONTINUING OPERATIONS	(0.00)	(0.00)
	BASIC AND DILUTED EARNINGS
	(LOSS) PER SHARE FROM DISCONTINUED OPERATIONS	(0.00)	(0.00)
	WEIGHTED AVERAGE
	NUMBER OF COMMON	906,039,537	308,859,321

SHARES OUTSTANDING

 

The accompanying Notes are an integral part of these Financial Statements

 

 

 

 

ENTEST BIOMEDICAL, INC.
( A Development Stage Company)
Consolidated Statement of Cash Flows
			Quarter Ended	Quarter Ended	From inception until
			November 30, 2013	November 30, 2012	November 30, 2013
			(unaudited)	(unaudited)	(unaudited)
	OPERATING ACTIVITIES
	Net (loss)		(510,963)	(681,436)	(5,435,582)
	Adjustments by operating  to reconcile net loss to net cah used activities:
		Depreciation Expense	0	2,073	16,125
		Amortization Expense	192	194	2,209
		Stock issued as Compensation to Employees	0	24,800	661,280
		Stock issued as Compensation to Consultants	0	6,000	532,142
		Preferred Stock issued for accrued compensation	0	0	2,000
	Change in operating assets and liabilities:
		(Increase) Decrease in Trade Accounts Receivable	0	2,268	0
		(Increase) Decrease in Inventory	0	10,298	0
		(Increase) Decrease in Employee Receivable	0	4,349	0
		Increase (Decrease) in Accounts Payable	(1,034)	18,184	100,580
		(Increase)Decrease in Due to Other
		(Increase) Decrease in Prepaid Expenses	0	0	(8,000)
		(Increase) Decrease in Due from Affiliate	6,232	4,245	(28,663)
		(Increase) Decrease in Deposits	0	1,151	0
		Increase(Decrease) in amortization of intangibles	0	0	16,667
		Increase (Decrease) in Accrued Expenses	33,441	26,562	291,752
		(Increase)Decrease on gain realized on cancellation
		of stock	0	0	(94,937)
		Increase(Decrease) in Loss on Impairment
		of Intangible Assets	0	0	683,333
		Net Cash Provided Used in Operating Activities	(472,132)	(581,312)	(3,261,094)
	INVESTING ACTIVITIES
		Purchase/Sale of Equipment
			0	0	(22,884)
		Net cash Provided by (Used in) Investing Activities	0	0	(22,884)
	FINANCING ACTIVITIES
		(Increase) Decrease in Goodwill from acquisition	0	405,000	0
		Noncash Loss on derecognition of assets	0	4,840	4,840
		Expenses incurred resulting from issuance of stock for
		less than par	420,369	49,294	476,712
		Increase (Decrease) in Common stock issued for cash	0	64,300	431,900
		(Increase) Decrease in Intangible Assets (net)	0	0	(2,299)
		Increase (Decrease) in Common stock issued
		for expenses	4,420	28,568	340,654
		Increase (Decrease) in Due to Affiliate	0	0	8,000
		Increase (Decrease) in Notes Payable	13,560	(37,424)	1,223,945
		Increase (Decrease) in Contributed Capital	0	0	274,161
		Increase (Decrease) in Additional paid in Capital	30,800	63,000	568,370
		Net Cash Provided by Financing Activities	469,149	577,578	3,326,283
	DISCONTINUED OPERATION
		Profit(Loss) from discontinued operations	(3,753)	(31,210)	(39,431)
		Net Increase in Cash	(6,736)	(34,944)	2,874
		Cash at Beginning of Period	9,610	42,737	0
		Cash at End of Period	2,874	7,793	2,874
Supplemental Disclosure of Noncash investing and financing activities:
Stock issued in payment of Debt			141,650	101,500	1,028,376
Stock issued in Acquisition of McDonald Animal Hospital			0	0	210,000
Stock issued pursuant to Titterington Agreement			0	0	700,000
The accompanying Notes are an integral part
of these Financial Statements

 

 

  

 

Entest BioMedical, Inc.

(A Development Stage Company)

Notes to Consolidated Financial Statements

As of November 30, 2013

 

 

 

NOTE 1. BASIS OF PRESENTATION

 

The interim financial statements included herein, presented in accordance with United States generally accepted accounting principles and stated in US dollars, have been prepared by Entest BioMedical, Inc. (“the Company”), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading.

 

These statements reflect all adjustments, consisting of normal recurring adjustments, which, in the opinion of management, are necessary for fair presentation of the information contained therein.  It is suggested that these condensed consolidated interim financial statements be read in conjunction with the financial statements of the Company for the period ended August 31, 2013 and notes thereto included in the Company's 10-K annual report.  The Company follows the same accounting policies in the preparation of interim reports.

 

 

NOTE 2.  ORGANIZATION AND DESCRIPTION OF BUSINESS

 

The Company was incorporated in the State of Nevada on September 24, 2008 as JB Clothing Corporation.  Until July 10, 2009, the Company’s principal business objective was the offering of active/leisure fashion design clothing.

 

On July 10, 2009 the Company abandoned its efforts in the field of active/leisure fashion design clothing when it acquired 100% of the share capital of Entest BioMedical, Inc., a California corporation, (“Entest CA”).

 

The Company’s current business consists of the development and commercialization of immunotherapeutic therapies for the veterinary market as well as the acquisition and operation of veterinary hospitals.

 

NOTE 3.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

A. BASIS OF ACCOUNTING

 

The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted an August 31 fiscal year-end. The Company recognizes revenue from services and product sales when the following four revenue recognition criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the selling price is fixed or determinable, and collectability is reasonably assured. Product sales and service revenues are recorded when the products are delivered and title passes to customers. The customer’s credit card is authorized and charged, or checks/cash are received at the time the services are rendered, thereby providing reasonable assurance of collectability.

 

B. PRINCIPLES OF CONSOLIDATION

 

The consolidated financial statements include the accounts of Entest CA, the Company’s wholly owned subsidiary. Significant inter-company transactions have been eliminated.

 

C. USE OF ESTIMATES

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

D. CASH EQUIVALENTS

 

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

 

E. PROPERTY AND EQUIPMENT

 

As of November 30, 2013 Property and Equipment consists of $1,919 of Computer equipment. No depreciation expense has been recorded with regards to this equipment as it has yet to be put into service

 

F. FAIR VALUE OF FINANCIAL INSTRUMENTS

 

Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:

 

Level 1:  Quoted prices in active markets for identical assets or liabilities

 

Level 2:  Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

 

Level 3:  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

The Company’s financial instruments as of November 30, 2013 consisted of $245,554 of Notes Payable, $8,000 due to TheraCyte, Inc. and $28,663 due from an affiliate. The fair value of all of the Company’s financial instruments as of November 30, 2013 were valued according to the Level 3 input. The carrying amount of the financial instruments is equal to the fair value as determined by the Company.

 

The Company has determined that there are no Level 1 or Level 2 inputs for determining the fair value of the Company’s financial instruments. Fair value was determined by the Company utilizing its own assumptions and estimation. There were no transfers between levels for the period presented.

 

G. INCOME TAXES

 

The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

 

The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of November 30, 2013 and August 31, 2013 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

 

The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established.

 

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

 

H.  BASIC EARNINGS (LOSS) PER SHARE

 

The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. All convertible debt has an anti-dilutive effect on the EPS, therefore Diluted earnings per share are the same as basic earnings per share.

 

NOTE 4.  RECENT ACCOUNTING PRONOUNCEMENTS

 

On May 2011, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2011-04, "Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs." The amendments in this update generally represent clarifications of Topic 820, but also include some instances where a particular principle or requirement for measuring fair value or disclosing information about fair value measurements has changed. This update results in common principles and requirements for measuring fair value and for disclosing information about fair value measurements in accordance with U.S. GAAP and IFRS. The amendments in this update are to be applied prospectively. The amendments are effective for interim and annual periods beginning after December 15, 2011. Early application is not permitted. The Company does not expect this guidance to have a significant impact on its consolidated financial position, results of operations or cash flows.

 

In June 2011, the FASB issued ASU No. 2011-05, "Presentation of Comprehensive Income." This update was amended in December 2011 by ASU No. 2011-12, "Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05." This update defers only those changes in update 2011-05 that relate to the presentation of reclassification adjustments. All other requirements in update 2011-05 are not affected by this update, including the requirement to report comprehensive income either in a single continuous financial statement or in two separate but consecutive financial statements. ASU No. 2011-05 and 2011-12 are effective for fiscal years (including interim periods) beginning after December 15, 2011. The Company does not expect this guidance to have a significant impact on its consolidated financial position, results of operations or cash flows.

 

In December 2011, the FASB issued ASU No. 2011-11, "Disclosures about Offsetting Assets and Liabilities." The amendments in this update require enhanced disclosures around financial instruments and derivative instruments that are either (1) offset in accordance with either ASC 210-20-45 or ASC 815-10-45 or (2) subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset in accordance with either ASC 210-20-45 or ASC 815-10-45. An entity should provide the disclosures required by those amendments retrospectively for all comparative periods presented. The amendments are effective during interim and annual periods beginning on or after January 1, 2013. The Company does not expect this guidance to have any impact on its consolidated financial position, results of operations or cash flows.

 

A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies.  Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

 

NOTE 5.  GOING CONCERN

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $5,507,155 during the period from August 22, 2008 (inception) through November 30, 2013. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Management plans to raise additional funds primarily by offering securities for cash.

 

On June 1, 2012 the Company entered into an Equity Purchase Agreement (the "June Purchase Agreement") with Southridge Partners II, LP, a Delaware limited partnership ("Southridge").

 

Under the terms of the June Purchase Agreement, Southridge will purchase, at the Company's election, up to $10,000,000 of the Company's registered common stock (the "Shares"). During the term of the Purchase Agreement, the Company may at any time deliver a "put notice" to Southridge thereby requiring Southridge to purchase a certain dollar amount of the Shares. Simultaneous with the delivery of such Shares, Southridge shall deliver payment for the Shares. Subject to certain restrictions, the purchase price for the Shares shall be equal to 91% of the average of the two lowest Closing Prices during the Valuation Period as such capitalized terms are defined in the Agreement.

 

The number of Shares sold to Southridge shall not exceed the number of such shares that, when aggregated with all other shares of common stock of the Company then beneficially owned by Southridge, would result in Southridge owning more than 9.99% of all of the Company's common stock then outstanding. Additionally, Southridge may not execute any short sales of the Company's common stock.

 

Any sale of Shares pursuant to the June Agreement is subject to a Registration Statement filed under the Securities Act of 1933 remaining effective for the sale by Southridge of those Shares.

 

June Agreement shall terminate (i) on the date on which Southridge shall have purchased Shares pursuant to this Agreement for an aggregate Purchase Price of $10,000,000, or (ii) on the date occurring 24 months from the date on which the June Agreement was executed and delivered by the Company and Southridge.

 

The Company has also agreed to pay the following to Capital Path Securities LLC for acting as the Company’s exclusive advisor and placement agent in connection with the June Purchase Agreement a  cash placement fee of 5% of funds received by the Company through the sale of Shares to Southridge as such funds are received by the Company.

 

On June 12, 2012 a registration statement on form S-1 was filed with the United States Securities and Exchange Commission registering 46,238,705 shares of the Company’s   common stock that will be put to Southridge pursuant to the June Agreement which was declared effective by the United States Securities and Exchange Commission on August 27, 2012.During the quarter ended November 30, 2012 the Company sold 37,640, 614 common shares for total consideration of $64,300 pursuant to the June Agreement.

 

NOTE 6.  NOTES PAYABLE 

 

As of November 30, 2013

 

Notes Payable:

Bio Technology Partners Business Trust		$	41,000
The Sherman Family Trust		$	98,200
Officer Loans (Note 7)		$	95,848
Venture Bridge Advisors		$	10,506
Total		$	245,554

 

As of August 31, 2013

 

Notes Payable:

Bio Technology Partners Business Trust		$	13,550
The Sherman Family Trust		$	98,200
Officer Loans (Note 6)		$	117,588
Venture Bridge Advisors		$	37,606
Southridge Partners II LLP		$	5,700
Total		$	272,644

 

Convertible Notes Payable

 

8% Convertible Notes Payable $101,000

 

Both of Bio Technology Partners Business Trust and Venture Bridge Advisors have provided lines of credit to the Company in the amount of $200,000 each or so much thereof as may be disbursed to, or for the benefit of the Company by Lender in Lender's sole and absolute discretion. The unpaid principal of these lines of credit bear simple interest at the rate of ten percent per annum. Interest is calculated based on the principal balance as may be adjusted from time to time to reflect additional advances or payments made hereunder. Principal balance and accrued interest shall become due and payable in whole or in part at the demand of the Lender. The Sherman Family Trust has provided a line of credit to the Company in the amount of $700,000 or so much thereof as may be disbursed to, or for the benefit of the Company by Lender in Lender's sole and absolute discretion. The unpaid principal of this line of credit bears simple interest at the rate of ten percent per annum. Interest is calculated based on the principal balance as may be adjusted from time to time to reflect additional advances or payments made hereunder. Principal balance and accrued interest shall become due and payable in whole or in part at the demand of the Lender.

 

NOTE 7.  RELATED PARTY TRANSACTIONS

 

As of November 30, 2013 the Company remains indebted to David R. Koos in the principal amount of $95,848 due and payable at the demand of David Koos and bearing simple interest at a rate of 15% per annum

 

As of November 30 , 2013 Bio-Matrix Scientific Group, Inc. (“BMSN”) , a major shareholder of the Company, is indebted to the Company in the amount of $28,663. This amount is non interest bearing and is due at the demand of the Company.

 

NOTE 8.  INCOME TAXES

 

As of November 30, 2013
Deferred tax assets:
Net operating tax carry forwards		$	1,877,073
Other			-0-

 

 

Gross deferred tax assets			1,877,073
Valuation allowance			(1,877,073)
Net deferred tax assets		$	-0-

 

As of  November 30 ,2013  the Company has a Deferred Tax Asset of $1,877,073 completely attributable to net operating loss carry forwards of approximately $5,520,802  (which expire 20 years from the date the loss was incurred) consisting of:

 

(a) $ 13,647 of Net Operating Loss carry forwards acquired in the reverse acquisition of Entest BioMedical, Inc., a California corporation, and

(b) $ 5,507,155 of Net Operating Loss carry forwards attributable to Entest BioMedical, Inc.

 

Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized. In addition, the reverse acquisition in which Entest BioMedical, Inc. was involved in 2009 has resulted in a change of control.  Internal Revenue Code Sec 382 limits the amount of income that may be offset by net operating loss (NOL) carryovers after an ownership change. As a result, the Company has recorded a valuation allowance reducing all deferred tax assets to $ -0-.

 

Income tax is calculated at the 34% Federal Corporate Rate.

 

NOTE 9.  ACQUISITION OF ENTEST CA

 

On July 10, 2009 the Company acquired 100% of Entest CA, a California corporation and wholly owned subsidiary of the Company, from BMSN for consideration consisting of (a) the issuance to BMSN of 10,000,000 newly issued common shares of Entest and (b) the return by Mr. Rick Plote of 10,000,000 shares of Entest’s common stock previously issued to him by Entest for cancellation.

 

NOTE 10.  ACQUISITION OF THE ASSETS OF PET POINTERS, INC.

 

On January 4, 2011Entest CA acquired from Pet Pointers, Inc., a California corporation doing business as McDonald Animal Hospital (“Seller”), and Dr. Gregory McDonald DVM (“McDonald”) all the goodwill from McDonald and assets of Seller except cash and accounts receivables used in connection with the operation of a veterinary medical clinic located at 225 S. Milpas Street, Santa Barbara, CA 93103 (the "Business").

 

Consideration for the acquisition consisted of:

 

   I. $70,000 in cash

 

   II. $210,000 of the Company’s common shares valued at the closing price per share as of January 4, 2011

 

   III. Payment of no more than $78,000 to a creditor of the Seller to be paid in monthly installments of $1,500 per month

 

   IV. Payment of no more than $25,000 to additional creditors of the Seller to be paid in monthly installments of $825 per month

 

   V. Payment of $50,000 to McDonald on the first business day of the fourth month following the closing of the acquisition (“Closing”).

 

NOTE 11. DISPOSITION OF THE ASSETS OF PET POINTERS, INC.

 

On November 28, 2012 the “Company executed an agreement (“Agreement”) with Gregory McDonald ("McDonald"), Pet Pointers, Inc. ("Pet Pointer") whereby Mc Donald and Pet Pointer would acquire from the Company all assets (with the exception of cash and accounts receivable) utilized by the Company in the operation of the McDonald Animal Hospital, a full service veterinary clinic owned and operated by the Company and located in Santa Barbara, California (“McDonald Asset Sale”).

On October 10, 2012 a Complaint (“Complaint”) was filed in the Superior Court of the State of California against the Company and David Koos by McDonald, a former employee of the Company, alleging breach of contract and breach of the covenant of good faith and dealing in connection with the assumption of lease obligations by the Company in connection with the acquisition of the assets of Pet Pointers, Inc breach of contract and breach of the covenant of good faith and dealing in connection with an employment agreement enters into with McDonald inc connection with the Acquisition, breach of contract in connection with the Acquisition purchase agreement, breach of the covenant of good faith and dealing in connection with the Acquisition purchase agreement, implied indemnity in connection to amounts owed by McDonald to Anthony and Judi Marinelli, the Internal Revenue Service, and the California Franchise Tax Board, intentional misrepresentation, negligent misrepresentation , failure to pay wages and violations of Sections 2802, 203, and 2806 of the California Labor Code. The Complaint sought judgment for nominal damages, actual damages, compensatory damages, lost wages, compensation, expenses wage benefits and penalties pursuant to California Labor Code Sections 203 et al, 2802 and 2806, indemnification, accrued interest, punitive damages, costs of suit and attorney’s fees.

As consideration to the Company for the assets acquired, McDonald and Pet Pointers provided to the Company a General release whereby McDonald and Pet Pointer waive, release and discharge the Company and their respective assignees, officers, directors, shareholders, boards, owners, employees, attorneys, agents, trustors, trustees, beneficiaries, heirs, successors, and representatives from all known and unknown claims, demands, causes of action, attorney's fees, costs, or expenses including: 

(1) All claims relating to the Complaint.

(2) Those owed by McDonald to Anthony and Judi Marinelli which the Company became obligated to pay on McDonald’s behalf pursuant to the asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc on January 4, 2011.

(3) Those amounts owed by McDonald to the Internal Revenue Service which the Company became obligated to pay on McDonald’s behalf pursuant to the asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc on January 4, 2011.

(4) Those amounts owed by McDonald to the California Franchise Tax Board which the Company became obligated to pay on McDonald’s behalf pursuant to the asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc on January 4, 2011.

Assets disposed of pursuant to the Agreement include approximately $4,840 of Property Plant and Equipment net of accumulated depreciation as well as all inventory held at the McDonald Animal Hospital.

Assets disposed of pursuant to the Agreement also include 

(i) Essentially all intellectual property, including computer software, utilized in connection with the operation of the McDonald Animal Hospital

(ii) All telephone numbers, fax numbers, service marks, trademarks, trade names, fictitious business names, websites, business email addresses, vendor lists, promotional materials, vendor records and any and all business records including, but not limited to, such items stored in computer memories, microfiche, paper record or by any other means relevant to the operation of the McDonald Animal Hospital.

(iii) All customer lists, customer contacts, and any and all customer records that are related to the McDonald Animal Hospital.

As a result of the agreement, the Company recorded a non-cash pre-tax charge for the impairment of goodwill recorded in connection with the acquisition of the McDonald Animal Hospital of approximately $405,000 for the quarter ended November 30, 2012.

Pursuant to the Agreement, the Company is obligated to make payment of $13,000 within five days of the Closing of the Agreement as such term is defined in the Agreement.

Pursuant to the Agreement, the Company agrees to waive, release and discharge McDonald and Pet Pointer from all known and unknown claims, demands, causes of action, attorney's fees, costs, or expenses.

 

NOTE 12. COMMITMENTS AND CONTINGECIES

 

On November 1, 2011, the Company entered into an agreement to lease approximately 2,320 square feet of office space beginning December 1, 2011 for a period of five years.

 

Rent to be charged to the Company pursuant to the lease is as follows:

 

$2,996 per month for the period beginning December 1, 2011 and ending November 30, 2012

$3,116 per month for the period beginning December 1, 2012 and ending November 30, 2013

$3,241 per month for the period beginning December 1, 2013 and ending November 30, 2014

$3,371 per month for the period beginning December 1, 2014 and ending November 30, 2015

$3,506 per month for the period beginning December 1, 2015 and ending November 30, 2016

 

This property is utilized as office space. The Company believes that the foregoing property is adequate to meet its current needs. While it is anticipated that the Company will require access to laboratory facilities in the future, the Company believes that access to such facilities are available from a variety of sources.

 

On May 24, 2012, a Complaint (“Complaint”) was filed in the U.S. Bankruptcy Court for the District of Oregon against the Company by Titterington Veterinary Services Inc. (“TVS”). The Complaint is an adversary proceeding filed by TVS arising from TVS’s bankruptcy case currently pending in U.S. Bankruptcy Court for the District of Oregon. The Complaint alleges Breach of Contract resulting from the Company’s alleged failure to pay certain expenses the Company was required to pay pursuant to an agreement with TVS, Dr. Ronald Titterington, DVM and Dr. Kathy Snell, DVM (“TVS Agreement”). TVS is seeking a judgment and money award against the Company in an amount to be proven at trial which TVS estimates in the Complaint to be up to $50,000. TVS is also seeking a judgment and order against the Company to provide an accounting of all revenues received by the Company pursuant to the TVS Agreement, all expenses paid, unpaid, and due and owing  pursuant to the TVS Agreement as well as a revenue share which TVS claims is due them pursuant to the TVS Agreement. TVS is also seeking a judgment requiring the Company to turn over a sum of money equal to expenses the Company was obligated to pay pursuant to the TVS Agreement. TVS is also seeking attorney’s fees and expenses.  The Company believes that the allegations in the complaint are without merit and intends to vigorously defend its interests in this matter. At this time, it is not possible to predict the ultimate outcome of these matters and an outcome unfavorable to the Company may have a material adverse effect on the Company. On September 19, 2012 the Plaintiff’s Claim for Relief for turnover and an accounting under 11 U.S.C. § 542 and the Plaintiff's Claim for Relief for attorney fees were dismissed with prejudice and , as per the claim of breach of contract, the proceeding was transferred to the United States Bankruptcy Court for the District of Southern California for all further proceedings.

 

There were no other legal proceedings against the Company with respect to matters arising in the ordinary course of business. The Company is not involved in any other litigation either as plaintiffs or defendants, and has no knowledge of any threatened or pending litigation against the Company.

 

On June 1, 2012 the Company entered into an Equity Purchase Agreement (the "June Purchase Agreement") with Southridge Partners II, LP, a Delaware limited partnership ("Southridge").

 

Under the terms of the June Purchase Agreement, Southridge will purchase, at the Company's election, up to $10,000,000 of the Company's registered common stock (the "Shares"). During the term of the Purchase Agreement, the Company may at any time deliver a "put notice" to Southridge thereby requiring Southridge to purchase a certain dollar amount of the Shares. Simultaneous with the delivery of such Shares, Southridge shall deliver payment for the Shares. Subject to certain restrictions, the purchase price for the Shares shall be equal to 91% of the average of the two lowest Closing Prices during the Valuation Period as such capitalized terms are defined in the Agreement.

 

The number of Shares sold to Southridge shall not exceed the number of such shares that, when aggregated with all other shares of common stock of the Company then beneficially owned by Southridge, would result in Southridge owning more than 9.99% of all of the Company's common stock then outstanding. Additionally, Southridge may not execute any short sales of the Company's common stock.

 

Any sale of Shares pursuant to the June Agreement is subject to a Registration Statement filed under the Securities Act of 1933 remaining effective for the sale by Southridge of those Shares.

 

June Agreement shall terminate (i) on the date on which Southridge shall have purchased Shares pursuant to this Agreement for an aggregate Purchase Price of $10,000,000, or (ii) on the date occurring 24 months from the date on which the June Agreement was executed and delivered by the Company and Southridge.

 

The Company has also agreed to pay the following to Capital Path Securities LLC for acting as the Company’s exclusive advisor and placement agent in connection with the June Purchase Agreement a  cash placement fee of 5% of funds received by the Company through the sale of Shares to Southridge as such funds are received by the Company.

 

NOTE 13. STOCKHOLDERS EQUITY

 

The stockholders' equity section of the Company contains the following classes of capital stock as of November 30, 2013:

 

Common Stock:

 

$0.001 par value, 2,000,000,000 shares authorized and 1,153,070,752 shares issued and outstanding as of November 30, 2013.

 

Preferred Stock:

 

$0.001 par value 5,000,000 shares authorized of which

 

(a)

100,000 are authorized as Series AA Preferred Stock , $.001 par value, of which 5,000 shares are issued and outstanding  as of  November 30, 2013  and

 

(b)

4,400,000 are authorized as Series B Preferred Stock of which 3,201,397 shares are issued and outstanding as of November 30, 2013.

 

Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series B Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.10 per share of Series B Preferred Stock (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series B Preferred Stock held by them.

 

If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series B Preferred Stock, then the entire net assets of the Company shall be distributed among the holders of the Series B Preferred Stock, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board..

 

Non Voting Convertible Preferred Stock having a $1.00 par value:

 

200,000 shares authorized of which 0 shares are issued and outstanding as of November 30, 2013.

 

Non Voting Convertible Preferred Stock shall convert at the option of the holder into shares of the corporation’s common stock at a conversion price equal to seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert.

 

“CLOSING PRICE" shall mean the closing bid price for the corporation’s common stock on the Principal Market on a Trading Day as reported by Bloomberg Finance L.P.

 

“PRINCIPAL MARKET" shall mean the principal trading exchange or market for the corporation’s common stock.

 

“TRADING DAY” shall mean a day on which the Principal Market shall be open for business.

 

NOTE 14. STOCK TRANSACTIONS

 

During the quarter ended November 30, 2013:

 

On September 4, 2013 The Company issued 27,887,324 of its common shares in satisfaction of $19,800 of convertible notes payable.

 

On September 16, 2013 The Company issued 28,000,000 of its common shares in satisfaction of $12,600 of convertible notes payable.

 

On September 20, 2013 The Company issued 20,820,513 of its common shares in satisfaction of $5,600 of convertible notes payable and $2,520 of accrued interest on convertible notes payable.

 

On September 23, 2013 The Company issued 39,325,397 of its common shares in conversion of 24,775 of the Company’s Non Voting Convertible Preferred Stock

 

On September 24, 2013 The Company issued 27,9487,18 of its common shares in satisfaction of $10,900 of convertible notes payable.

 

On September 27, 2013 The Company issued 27,9487,18 of its common shares in satisfaction of $10,900 of convertible notes payable.

 

On September 30, 2013 The Company issued 60,000,000 of its common shares in satisfaction of $13,550 of notes payable.

 

 On October 2, 2013 The Company issued 24,848,485 of its common shares in satisfaction of $8,200 of convertible notes payable.

 

On October 8, 2013 The Company issued 27,727,273 of its common shares in satisfaction of $6,100 of convertible notes payable.

 

On October 9, 2013 The Company issued 28,000,000 of its common shares in satisfaction of $5,600 of convertible notes payable.

 

On October 10, 2013 The Company issued 27,777,778 of its common shares in satisfaction of $5,000 of convertible notes payable.

 

On October 14, 2013 The Company issued 60,000,000 of its common shares in satisfaction of $13,550 of notes payable.

 

On October 15, 2013 The Company issued 27,777,778 of its common shares in satisfaction of $5,000 of convertible notes payable.

 

On October 18, 2013 The Company issued 20,652,000 of its common shares in satisfaction of $3,300 of convertible notes payable.

 

On October 22, 2013 The Company issued 55,000,000 of its common shares in satisfaction of $6,600 of convertible notes payable.

 

On October 24, 2013 The Company issued 27,500,000 of its common shares in satisfaction of $1,400 of convertible notes payable and $1,900 of accrued interest on convertible notes payable.

 

On November 23, 2013 The Company issued 60,000,000 of its common shares in satisfaction of $13,550 of notes payable.

 

 

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

CERTAIN FORWARD-LOOKING INFORMATION

 

Information provided in this Quarterly report on Form 10Q may contain forward-looking statements within the meaning of Section 21E or Securities Exchange Act of 1934 that are not historical facts and information. These statements represent the Company's expectations or beliefs, including, but not limited to, statements concerning future and operating results, statements concerning industry performance, the Company's operations, economic performance, financial conditions, margins and growth in sales of the Company's products, capital expenditures, financing needs, as well assumptions related to the forgoing. For this purpose, any statements contained in this Quarterly Report that are not statement of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based on current expectations and involve various risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. The Company's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by the Company with the Securities and Exchange Commission, including the Company's most recent Form 10K for the year ended August 31, 2013. All references to” We”, “Us”, “Company” or the “Company” refer to Entest BioMedical, Inc.

 

Material Changes in Financial Condition

 

As of November 30, 2013, we had Cash on Hand of $2,874 and as of August 31, 2013 we had Cash on Hand of $9,610.

 

The decrease in Cash on Hand of approximately 70 %  is primarily attributable to expenses  incurred by the Company in the operation of its business and the reversal of $3,753 of credit card purchase revenues previously recognized by the Company’s discontinued subsidiary the McDonald Animal Hospital.

 

 As of November 30, 2013, we had Amounts Due from Affiliate of $28,663 and as of August 31, 2013 we had Amounts Due from Affiliate of $34,895.

 

The decrease in Amounts Due from Affiliate of approximately 17% is attributable to $6,232 of rental expenses paid on behalf of the Company by Bio Matrix Scientific Group, Inc.

 

As of November 30, 2013 we had Intangible Assets of $78 and as of August 31, 2013 we had Intangible Assets of $270.

 

The decrease in Intangible Assets of approximately 71% is primarily attributable to the recognition of amortization expense.

 

As of November 30, 2013 we had Notes Payable of $245,554 and as of August 31, 2013 we had Notes Payable of $272,644.

 

The decrease in Notes Payable of approximately 9% is primarily attributable to:

(a)

Satisfaction of $40,650 of principal amount of notes payable through the issuance of the Company’s common shares during the quarter ended November 30, 2013

(b)

Net payments to David Koos of $21,740 during the quarter ended November 30, 2013

(c)

Forgiveness by the lender of $5,750 of principal debt

 

Offset by:

 

(a)

$41,000 of new borrowings from a third party lender during the quarter ended November 30, 2013

 

 

 

As of November 30, 2013 we had Convertible Notes Payable of $0 and as of August 31, 2013 we had Notes Payable of $101,000.

 

The decrease in Convertible Notes Payable of 100% is attributable to conversions into the common shares of the Company.

 

As of November 30, 2013 we had Accrued Expenses of $291,754 and as of August 31, 2013 we had Accrued Expenses of $258,313.

 

The increase in Accrued Expenses of approximately 13% is primarily attributable to:

 

	(a)	Accrual of $30,000 in salary owed to the Company’s CEO over the course of the quarter ended November 30, 2013
	(b)	Accrual of $3,441 of interest expense incurred over the course of the quarter ended November 30, 2013.

 

 

Material Changes in Results of Operations

 

Revenues from continuing operations were $0 for the three months ended November 30, 2013 and -0- for the three months ended November 30, 2012.  Net Losses from continuing operations were $510,963 for the three months ended November 30, 2013 and $681,436 for the same period ended 2012.

 

The decrease in Net Losses from continuing operations of approximately 25% is primarily attributable to:

 

	(a)	Recognition of a $22,906 one time loss on assets disposed of in the disposition of the McDonald Animal Hospital during the quarter ended November 30, 2012.
	(b)	Recognition of a Goodwill impairment charge of $405,000 attributable to the disposition as of November 30, 2012 of certain assets related to the McDonald Animal Hospital   (c)     Recognition of $26,868 of expenses related to common shares issued pursuant to contractual obligations to certain convertible noteholders recognized during the quarter ended November 30, 2012. (d)     Greater General and Administrative, Consulting, and interest Expenses recognized during the quarter ended November 30, 2012 (e)     Interest expense attributable to amortization of discounts recognized on convertible notes payable of $61,904 recognized during the quarter ended November 30, 2012 (f)      The recognition of $5,700 in Other Income during the quarter ended November 30, 2013 attributable to the forgiveness by the lender of $5,700 of Notes Payable   Offset by   (a)     A gain on derecognition of liabilities of $61,168 recorded during the quarter ended November 30, 2012 attributable to the disposition as of November 30, 2012 of the McDonald Animal Hospital (b)     Lower rental expense recognized during the quarter ended November 30, 2012 when compared to the quarter ended November 30, 2013

 

 

Liquidity and Capital Resources

 

As of  November 30, 2013 we had $2,874  cash on hand and current liabilities of $645,889 such liabilities consisting of Accounts Payable, Notes Payable, Amounts due to Affiliates / Others and Accrued Expenses.

 

We feel we will not be able to satisfy its cash requirements over the next twelve months and shall be required to seek additional financing.

 

We currently plan to raise additional funds primarily by obtaining governmental and non-governmental grants, offering securities for cash and acquiring existing veterinary clinics with the ability to generate cash flow to fund operations.

 
We have yet to decide what type of offering we will use or how much capital we will raise. There is no guarantee that we will be able to raise any capital through any type of offerings. We can give no assurance that any governmental or non-governmental grant will be obtained by us despite our best efforts. We cannot assure that we will be successful in obtaining additional financing necessary to implement our business plan.  We have not received any commitment or expression of interest from any financing source that has given us any assurance that we will obtain the amount of additional financing in the future that we currently anticipate.  For these and other reasons, we are not able to assure that we will obtain any additional financing or, if we are successful, that we can obtain any such financing on terms that may be reasonable in light of our current circumstances.

 

On June 1, 2012 the Company entered into an Equity Purchase Agreement (the "June Purchase Agreement") with Southridge Partners II, LP, a Delaware limited partnership ("Southridge").

 

Under the terms of the June Purchase Agreement, Southridge will purchase, at the Company's election, up to $10,000,000 of the Company's registered common stock (the "Shares"). During the term of the Purchase Agreement, the Company may at any time deliver a "put notice" to Southridge thereby requiring Southridge to purchase a certain dollar amount of the Shares. Simultaneous with the delivery of such Shares, Southridge shall deliver payment for the Shares. Subject to certain restrictions, the purchase price for the Shares shall be equal to 91% of the average of the two lowest Closing Prices during the Valuation Period as such capitalized terms are defined in the Agreement.

 

The number of Shares sold to Southridge shall not exceed the number of such shares that, when aggregated with all other shares of common stock of the Company then beneficially owned by Southridge, would result in Southridge owning more than 9.99% of all of the Company's common stock then outstanding. Additionally, Southridge may not execute any short sales of the Company's common stock.

 

Any sale of Shares pursuant to the June Agreement is subject to a Registration Statement filed under the Securities Act of 1933 remaining effective for the sale by Southridge of those Shares.

 

June Agreement shall terminate (i) on the date on which Southridge shall have purchased Shares pursuant to this Agreement for an aggregate Purchase Price of $10,000,000, or (ii) on the date occurring 24 months from the date on which the June Agreement was executed and delivered by the Company and Southridge.

 

The Company has also agreed to pay the following to Capital Path Securities LLC for acting as the Company’s exclusive advisor and placement agent in connection with the June Purchase Agreement a  cash placement fee of 5% of funds received by the Company through the sale of Shares to Southridge as such funds are received by the Company.

 

On June 12, 2012 a registration statement on form S-1 was filed with the United States Securities and Exchange Commission registering 46,238,705 shares of the Company’s   common stock that will be put to Southridge pursuant to the June Agreement which was declared effective by the United States Securities and Exchange Commission on August 27, 2012.

 

During the quarter ended November 30, 2012 the Company sold 37,640, 604 common shares for total consideration of $64,300 pursuant to the June Agreement. 

 

During the quarter ended November 30, 2013 the Company incurred net cash borrowings of $19,260.

 

 

We were not party to any material commitments for capital expenditures as of the end of the quarter ended November 30, 2013.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

As a smaller reporting company, as defined by Rule 229.10(f) (1) of Regulation S-K, we are not required to provide the information required by this Item. We have chosen to disclose, however, that we have not engaged in any transactions, issued or bought any financial instruments or entered into any contracts that are required to be disclosed in response to this item.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of David Koos, who is the Company's Principal Executive Officer/Principal Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures. The Company's disclosure controls and procedures are designed to provide a reasonable level of assurance of achieving the Company's disclosure control objectives. The Company's Principal Executive Officer/Principal Financial Officer has concluded that the Company's disclosure controls and procedures are, in fact, effective at this reasonable assurance level as of the period covered.

 

Changes in Internal Controls over Financial Reporting

 

In connection with the evaluation of the Company's internal controls during the period commencing on September 1, 2013 and ending on November 30, 2013, David Koos, who is both the Company's Principal Executive Officer and Principal Financial Officer has determined that there were no changes to the Company's internal controls over financial reporting that have been materially affected, or is reasonably likely to materially effect, the Company's internal controls over financial reporting.

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

On May 24, 2012, a Complaint (“Complaint”) was filed in the U.S. Bankruptcy Court for the District of Oregon against the Company by Titterington Veterinary Services Inc. (“TVS”). The Complaint is an adversary proceeding filed by TVS arising from TVS’s bankruptcy case currently pending in U.S. Bankruptcy Court for the District of Oregon. The Complaint alleges Breach of Contract resulting from the Company’s alleged failure to pay certain expenses the Company was required to pay pursuant to an agreement with TVS, Dr. Ronald Titterington, DVM and Dr. Kathy Snell, DVM (“TVS Agreement”). TVS is seeking a judgment and money award against the Company in an amount to be proven at trial which TVS estimates in the Complaint to be up to $50,000. TVS is also seeking a judgment and order against the Company to provide an accounting of all revenues received by the Company pursuant to the TVS Agreement, all expenses paid, unpaid, and due and owing pursuant to the TVS Agreement as well as a revenue share which TVS claims is due them pursuant to the TVS Agreement. TVS is also seeking a judgment requiring the Company to turn over a sum of money equal to expenses the Company was obligated to pay pursuant to the TVS Agreement. TVS is also seeking attorney’s fees and expenses. The Company believes that the allegations in the complaint are without merit and intends to vigorously defend its interests in this matter. At this time, it is not possible to predict the ultimate outcome of these matters and an outcome unfavorable to the Company may have a material adverse effect on the Company. On September 19, 2012 the Plaintiff’s Claim for Relief for turnover and an accounting under 11 U.S.C. § 542 and the Plaintiff's Claim for Relief for attorney fees were dismissed with prejudice and , as per the claim of breach of contract, the proceeding was transferred to the United States Bankruptcy Court for the District of Southern California for all further proceedings.

 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

 

On September 4, 2013 The Company issued 27,887,324 of its common shares (“Shares) in satisfaction of $19,800 of convertible notes payable.

 

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The Shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the Shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.

 

On September 16, 2013 The Company issued 28,000,000 of its common shares (“Shares”) in satisfaction of $12,600 of convertible notes payable.

 

 The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The Shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the Shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.

 

On September 20, 2013 The Company issued 20,820,513 of its common shares (“Shares”) in satisfaction of $5,600 of convertible notes payable and $2,520 of accrued interest on convertible notes payable.

 

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The Shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the Shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.

 

On September 23, 2013 The Company issued 39,325,397 of its common shares (“Shares”) in conversion of 24,775 of the Company’s Non Voting Convertible Preferred Stock

 

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The Shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the Shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.

 

On September 24, 2013 The Company issued 27,9487,18 of its common shares (“Shares”) in satisfaction of $10,900 of convertible notes payable.

 

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The Shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the Shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.

 

On September 27, 2013 The Company issued 27,9487,18 of its common shares (“Shares”) in satisfaction of $10,900 of convertible notes payable.

 

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The Shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the Shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.

 

On September 30, 2013 The Company issued 60,000,000 of its common shares (“Shares”) in satisfaction of $13,550 of notes payable.

 

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The Shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the Shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.

 

 On October 2, 2013 The Company issued 24,848,485 of its common shares (“Shares”) in satisfaction of $8,200 of convertible notes payable.

 

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The Shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the Shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.

 

On October 8, 2013 The Company issued 27,727,273 of its common shares (“Shares”) in satisfaction of $6,100 of convertible notes payable.

 

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The Shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the Shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.

 

On October 9, 2013 The Company issued 28,000,000 of its common shares (“Shares”) in satisfaction of $5,600 of convertible notes payable.

 

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The Shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the Shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.

 

On October 10, 2013 The Company issued 27,777,778 of its common shares (“Shares”) in satisfaction of $5,000 of convertible notes payable.

 

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The Shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the Shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.

 

On October 14, 2013 The Company issued 60,000,000 of its common shares (“Shares”) in satisfaction of $13,550 of notes payable.

 

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The Shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the Shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.

 

On October 15, 2013 The Company issued 27,777,778 of its common shares (“Shares”) in satisfaction of $5,000 of convertible notes payable.

 

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The Shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the Shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.

 

On October 18, 2013 The Company issued 20,652,000 of its common shares (“Shares”) in satisfaction of $3,300 of convertible notes payable.

 

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The Shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the Shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.

 

On October 22, 2013 The Company issued 55,000,000 of its common shares (“Shares”) in satisfaction of $6,600 of convertible notes payable.

 

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The Shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the Shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.

 

On October 24, 2013 The Company issued 27,500,000 of its common shares (“Shares”) in satisfaction of $1,400 of convertible notes payable and $1,900 of accrued interest on convertible notes payable.

 

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The Shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the Shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.

 

On November 23, 2013 The Company issued 60,000,000 of its common shares (“Shares”) in satisfaction of $13,550 of notes payable.

 

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The Shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the Shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares. 

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Reserved

 

None.

 

Item 5. Other Information

 

None.

 

Item 6. Exhibits

 

31.1	Certification of Chief Executive Officer
31.2	Certification of  Chief Financial Officer
32.1	Certification of Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 

 

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the Company caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Entest BioMedical, Inc.
	a Nevada corporation
By:	/s/ David R. Koos
	David R. Koos
	Chief Executive Officer
	Date: January 16, 2014